|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
WO2003035835A2
(en)
*
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
WO2007066106A1
(en)
*
|
2005-12-06 |
2007-06-14 |
Domantis Limited |
Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
|
|
WO2004043345A2
(en)
*
|
2002-11-08 |
2004-05-27 |
Kin-Ping Wong |
Extract of trapa natans and methods of using the same
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
CN101044164A
(zh)
|
2004-07-20 |
2007-09-26 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂，组合，以及其用途
|
|
AR052056A1
(es)
*
|
2004-12-17 |
2007-02-28 |
Genentech Inc |
Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo
|
|
FR2893622B1
(fr)
|
2005-11-24 |
2007-12-21 |
Commissariat Energie Atomique |
Composition a base de caprolactame,procede de fabrication d'un element d'etancheite,et reservoir
|
|
AU2012204022C1
(en)
*
|
2005-12-02 |
2014-02-20 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
CN101370832B
(zh)
*
|
2005-12-02 |
2014-07-02 |
健泰科生物技术公司 |
结合多肽及其用途
|
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
ES2388932T3
(es)
*
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
|
WO2007120334A2
(en)
|
2005-12-15 |
2007-10-25 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
TWI596111B
(zh)
*
|
2006-01-05 |
2017-08-21 |
建南德克公司 |
抗ｅｐｈｂ４抗體及使用該抗體之方法
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
CA2638823A1
(en)
|
2006-02-13 |
2007-08-23 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
DK1989231T3
(en)
|
2006-03-21 |
2015-08-24 |
Genentech Inc |
COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
|
|
KR100981202B1
(ko)
*
|
2006-05-31 |
2010-09-10 |
한화케미칼 주식회사 |
Ｖｃａｍ－１ 특이적 단일클론항체
|
|
SG175615A1
(en)
|
2006-06-06 |
2011-11-28 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
|
RU2415869C2
(ru)
*
|
2006-06-06 |
2011-04-10 |
Дженентек, Инк. |
Антитела против dll4 и способы их применения
|
|
CL2007002404A1
(es)
*
|
2006-08-21 |
2008-04-18 |
Hoffmann La Roche |
Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
|
|
US10118970B2
(en)
*
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
|
US20090098529A1
(en)
|
2006-10-16 |
2009-04-16 |
Nanhai Chen |
Methods for attenuating virus strains for diagnostic and therapeutic uses
|
|
CU23636A1
(es)
|
2006-11-01 |
2011-03-21 |
Ct Ingenieria Genetica Biotech |
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
|
|
JP2010512407A
(ja)
*
|
2006-12-11 |
2010-04-22 |
ジェネンテック インコーポレイテッド |
新生物を処置するための組成物および方法
|
|
AU2007333735A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
|
AR065092A1
(es)
*
|
2007-02-01 |
2009-05-13 |
Genentech Inc |
TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS
|
|
JP2010518115A
(ja)
|
2007-02-09 |
2010-05-27 |
ジェネンテック， インコーポレイテッド |
抗Ｒｏｂｏ４抗体およびそれらのための使用
|
|
US20090075378A1
(en)
*
|
2007-02-20 |
2009-03-19 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US7977313B2
(en)
*
|
2007-04-27 |
2011-07-12 |
Affinergy, Inc. |
Methods and compositions for promoting localization of pharmaceutically active agents to bone
|
|
GB0709333D0
(en)
|
2007-05-15 |
2007-06-20 |
Smart Targeting Ltd |
Binding protein
|
|
EP2158215B1
(en)
*
|
2007-05-17 |
2015-04-22 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
|
US7879369B2
(en)
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
|
AU2013205269B2
(en)
*
|
2007-11-09 |
2016-05-19 |
Affitech Research As |
Anti-VEGF antibody compositions and methods
|
|
JP5809415B2
(ja)
*
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ，インコーポレーテッド |
抗ｖｅｇｆ抗体の組成物および方法
|
|
BRPI0817063A2
(pt)
|
2007-11-09 |
2015-03-24 |
Genentch Inc |
"métodos de inibição, para o tratamento de uma condição patológica, para a inibição de linfagiogênese tumoral, de inibição ou prevenção,de desorganização, para inibição de crescimento de tumor, de tratamento, de acentuação da eficácia de um agente anti-angiogênese e antagonista de alk-1
|
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-ｖｅｇｆ抗體
|
|
AU2015200714B2
(en)
*
|
2007-11-30 |
2017-01-12 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
AU2013204108B2
(en)
*
|
2007-11-30 |
2014-11-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
JP5523345B2
(ja)
|
2008-01-18 |
2014-06-18 |
ジェネンテック， インコーポレイテッド |
Ｋ６３結合型ポリユビキチンを標的とする方法と組成物
|
|
KR102449659B1
(ko)
|
2008-03-18 |
2022-09-29 |
제넨테크, 인크. |
항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
|
|
WO2009120922A2
(en)
*
|
2008-03-27 |
2009-10-01 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
|
AU2009241589B2
(en)
*
|
2008-04-29 |
2013-10-10 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
MX347972B
(es)
|
2008-06-25 |
2017-05-22 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles que inhiben el vegf.
|
|
MX2011000039A
(es)
*
|
2008-07-02 |
2011-05-31 |
Emergent Product Dev Seattle |
Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos.
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
|
MX2011002082A
(es)
*
|
2008-08-29 |
2011-06-20 |
Genentech Inc |
Diagnostico y tratamientos para los tumores independientes del vegf.
|
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
WO2010045193A1
(en)
|
2008-10-14 |
2010-04-22 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
WO2010056893A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Imclone Llc |
Humanization and affinity-optimization of antibodies
|
|
EP2361085B9
(en)
|
2008-11-22 |
2019-01-02 |
F.Hoffmann-La Roche Ag |
Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
|
|
CA2746120A1
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Methods and compositions for diagnostic use in cancer patients
|
|
JP6051048B2
(ja)
|
2009-03-25 |
2016-12-21 |
ジェネンテック， インコーポレイテッド |
新規な抗α５β１抗体及びその使用
|
|
AU2010230563A1
(en)
*
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
|
SI2417156T1
(sl)
|
2009-04-07 |
2015-06-30 |
Roche Glycart Ag |
Trivalentna, bispecifiäśna protitelesa
|
|
EP3009454A3
(en)
|
2009-04-20 |
2016-10-19 |
Oxford Bio Therapeutics Limited |
Antibodies specific to cadherin-17
|
|
RU2011147051A
(ru)
*
|
2009-04-20 |
2013-05-27 |
Дженентек, Инк. |
Адъювантная терапия рака
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
SG10201510152RA
(en)
|
2009-07-13 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
|
EP2464220A4
(en)
|
2009-08-13 |
2014-05-07 |
Crystal Bioscience Inc |
Transgenic animal for the production of antibodies with minimal complementarity-determining regions
|
|
CA2770321A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Biological markers for monitoring patient response to vegf antagonists
|
|
TWI451875B
(zh)
|
2009-08-15 |
2014-09-11 |
建南德克公司 |
用於治療先前治療過之乳癌之抗－血管新生療法
|
|
BR112012004710A2
(pt)
|
2009-09-01 |
2016-08-16 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e uso das mesmas
|
|
EP2475996A1
(en)
|
2009-09-11 |
2012-07-18 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
JP5606537B2
(ja)
|
2009-09-17 |
2014-10-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における診断使用のための方法及び組成物
|
|
WO2011044133A2
(en)
*
|
2009-10-05 |
2011-04-14 |
Opsonic Therapeutics Inc. |
High affinity adaptor molecules for redirecting antibody specifity
|
|
PH12012500691A1
(en)
|
2009-10-15 |
2012-11-12 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
RU2546008C2
(ru)
*
|
2009-10-21 |
2015-04-10 |
Дженентек, Инк. |
Генетические полиморфизмы при возрастной дегенерации желтого пятна
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP3778917A3
(en)
*
|
2009-12-04 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
|
AR079704A1
(es)
|
2009-12-23 |
2012-02-15 |
Genentech Inc |
Anticuerpos anti-bv8 y sus usos
|
|
US20110171231A1
(en)
*
|
2010-01-12 |
2011-07-14 |
Carlos Bais |
ANTI-PlGF ANTIBODIES AND METHODS USING SAME
|
|
KR20180028561A
(ko)
|
2010-02-23 |
2018-03-16 |
제넨테크, 인크. |
난소암의 치료를 위한 항혈관신생 요법
|
|
CN102167740B
(zh)
*
|
2010-02-25 |
2014-06-04 |
上海百迈博制药有限公司 |
一种全人源抗vegf单克隆抗体、其制备方法及用途
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
TWI426920B
(zh)
*
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
CN102947335B
(zh)
|
2010-04-15 |
2018-11-06 |
基因泰克公司 |
抗多聚遍在蛋白抗体及使用方法
|
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
NZ605260A
(en)
*
|
2010-06-14 |
2013-12-20 |
Joseph King Allan |
Anti-vegf antibodies and uses thereof
|
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
|
WO2012010551A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
|
AR082461A1
(es)
|
2010-08-03 |
2012-12-12 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
MX2013002270A
(es)
|
2010-08-26 |
2013-05-14 |
Abbvie Inc |
Inmonoglubinas de dominio variable doble y usos de las mismas.
|
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
WO2012054084A2
(en)
*
|
2010-10-20 |
2012-04-26 |
Oxford Biotherapeutics Ltd. |
Antibodies
|
|
TW201300417A
(zh)
|
2010-11-10 |
2013-01-01 |
Genentech Inc |
用於神經疾病免疫療法之方法及組合物
|
|
AU2011329125B2
(en)
|
2010-11-15 |
2015-07-30 |
Five Prime Therapeutics, Inc. |
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
|
|
US20130236467A1
(en)
*
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CU23895B1
(es)
|
2010-12-28 |
2013-05-31 |
Biorec Sa |
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
JP6161541B2
(ja)
*
|
2011-02-03 |
2017-07-12 |
ゾーマ テクノロジー リミテッド |
細菌中の機能的タンパク質発現を向上させるための方法および物質
|
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
|
WO2012130831A1
(en)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Antibody fc variants
|
|
WO2012135759A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and abiraterone, and methods of use
|
|
EP3549952A1
(en)
|
2011-04-20 |
2019-10-09 |
Acceleron Pharma Inc. |
Endoglin polypeptides and uses thereof
|
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
US10466160B2
(en)
|
2011-08-01 |
2019-11-05 |
Celsee Diagnostics, Inc. |
System and method for retrieving and analyzing particles
|
|
US9103754B2
(en)
|
2011-08-01 |
2015-08-11 |
Denovo Sciences, Inc. |
Cell capture system and method of use
|
|
US9321844B2
(en)
|
2011-08-05 |
2016-04-26 |
Genentech, Inc. |
Anti-polyubiquitin antibodies
|
|
CN103890008A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
在顽固性肿瘤中抑制血管发生
|
|
MX2014002990A
(es)
|
2011-09-19 |
2014-05-21 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
|
|
JP6170496B2
(ja)
|
2011-09-23 |
2017-07-26 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
|
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
EP2788769A1
(en)
|
2011-12-05 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
|
|
EP2793941A1
(en)
|
2011-12-23 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Articles of manufacture and methods for co-administration of antibodies
|
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
|
KR20140114415A
(ko)
|
2012-01-13 |
2014-09-26 |
제넨테크, 인크. |
Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
|
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
|
AU2013231410B2
(en)
|
2012-03-13 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of ovarian cancer
|
|
SG10201509939PA
(en)
|
2012-03-30 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
TWI641687B
(zh)
*
|
2012-05-29 |
2018-11-21 |
美商再生元醫藥公司 |
生產細胞株增強子
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
US9107926B2
(en)
|
2012-06-08 |
2015-08-18 |
Genentech, Inc. |
Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
|
WO2013188403A1
(en)
*
|
2012-06-11 |
2013-12-19 |
Syngenta Participations Ag |
Producing solids and related mother liquors
|
|
HK1202334A1
(en)
|
2012-06-26 |
2015-09-25 |
霍夫曼-拉罗奇有限公司 |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
|
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
HRP20181595T1
(hr)
|
2012-07-13 |
2018-12-14 |
Roche Glycart Ag |
Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti
|
|
CA2928851A1
(en)
|
2012-07-19 |
2014-01-23 |
Alethia Biotherapeutics Inc. |
Anti-siglec-15 antibodies
|
|
KR20190088571A
(ko)
|
2012-08-07 |
2019-07-26 |
제넨테크, 인크. |
교모세포종의 치료를 위한 조합 요법
|
|
RU2666990C2
(ru)
|
2012-08-13 |
2018-09-13 |
Дженентек, Инк. |
Антитела к jagged и способы их применения
|
|
US12024568B2
(en)
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
|
CA2890263C
(en)
|
2012-11-01 |
2020-03-10 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
US20140154255A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
|
US10138519B2
(en)
*
|
2012-12-28 |
2018-11-27 |
Quest Diagnostics Investments Incorporated |
Universal sanger sequencing from next-gen sequencing amplicons
|
|
EP2956476B1
(en)
|
2013-02-18 |
2019-12-25 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
EP2968553B1
(en)
|
2013-03-13 |
2020-08-12 |
F.Hoffmann-La Roche Ag |
Antibody formulations
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
|
|
KR20150139955A
(ko)
|
2013-04-09 |
2015-12-14 |
보스톤 바이오메디칼, 인크. |
암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
|
|
CA2909689A1
(en)
|
2013-05-23 |
2014-11-27 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
|
KR101541478B1
(ko)
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
|
US10391490B2
(en)
|
2013-05-31 |
2019-08-27 |
Celsee Diagnostics, Inc. |
System and method for isolating and analyzing cells
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
SI3041513T1
(sl)
|
2013-09-08 |
2020-11-30 |
Kodiak Sciences Inc. |
Zwitterionski polimerni konjugati faktorja VIII
|
|
WO2015052230A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
|
EA202090707A1
(ru)
|
2013-10-25 |
2020-12-30 |
Акселерон Фарма, Инк. |
Эндоглиновые пептиды для лечения фиброзных заболеваний
|
|
WO2015081290A1
(en)
|
2013-11-27 |
2015-06-04 |
Inis Biotech Llc |
Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
|
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量（ｈｍｗ）タウ種およびその用途
|
|
JP2016530244A
(ja)
*
|
2013-12-31 |
2016-09-29 |
ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ |
抗ｖｅｇｆ抗体及びその使用
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
CN106536561A
(zh)
|
2014-05-01 |
2017-03-22 |
豪夫迈·罗氏有限公司 |
抗‑因子d抗体变体及其用途
|
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック， インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
MX2017006094A
(es)
|
2014-11-10 |
2017-07-19 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos.
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
|
AU2016262100B2
(en)
|
2015-05-12 |
2021-10-14 |
Syntimmune, Inc. |
Humanized affinity matured anti-FcRn antibodies
|
|
BR112017026025A2
(pt)
|
2015-06-03 |
2018-08-14 |
Boston Biomedical Inc |
composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
|
|
TW201711702A
(zh)
|
2015-06-04 |
2017-04-01 |
應克隆公司 |
使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
MA42924A
(fr)
|
2015-09-23 |
2018-08-01 |
Hoffmann La Roche |
Variants optimisés d'anticorps anti-vegf
|
|
CN108290957B
(zh)
|
2015-10-30 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
抗-HtrA1抗体及其使用方法
|
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
|
HK1257422A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
|
MX2018005226A
(es)
|
2015-10-30 |
2019-04-29 |
Genentech Inc |
Formulaciones de anticuerpo anti-factor d.
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
JP6910963B2
(ja)
|
2016-01-06 |
2021-07-28 |
株式会社オーダーメードメディカルリサーチ |
高親和性抗ｖｅｇｆ抗体
|
|
JP6925981B2
(ja)
|
2016-01-06 |
2021-08-25 |
株式会社オーダーメードメディカルリサーチ |
Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
CN108883182A
(zh)
|
2016-04-15 |
2018-11-23 |
伊莱利利公司 |
用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
|
|
EP3442573A1
(en)
|
2016-04-15 |
2019-02-20 |
Eli Lilly and Company |
Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
|
|
WO2017181111A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
ES2864211T3
(es)
|
2016-04-25 |
2021-10-13 |
Syntimmune Inc |
Anticuerpos anti-FcRn humanizados con maduración de la afinidad
|
|
EP3463456A1
(en)
|
2016-06-03 |
2019-04-10 |
ImClone LLC |
Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
|
|
WO2018007615A1
(en)
|
2016-07-07 |
2018-01-11 |
The European Molecular Biology Laboratory |
Viral polypeptide fragments that bind cellular pol ii c-terminal domain (ctd) and their uses
|
|
WO2018009811A1
(en)
|
2016-07-08 |
2018-01-11 |
Genentech, Inc. |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
|
JP7050702B2
(ja)
|
2016-07-08 |
2022-04-08 |
ジェネンテック， インコーポレイテッド |
Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
|
|
CN109477843A
(zh)
|
2016-07-15 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
用于检测总vegf-a的水平的方法和手段
|
|
US20210293786A1
(en)
*
|
2016-08-08 |
2021-09-23 |
Konica Minolta, Inc. |
Method Relating to Evaluation of Tumor Tissue of Experimental Animal
|
|
CN110248674B
(zh)
*
|
2016-09-07 |
2021-10-26 |
萨辛生命科学有限公司 |
针对vegf的合成抗体及其用途
|
|
CN109790215B
(zh)
|
2016-09-29 |
2023-06-30 |
北京韩美药品有限公司 |
异源二聚体免疫球蛋白构建体和其制备方法
|
|
JP2019534888A
(ja)
|
2016-10-28 |
2019-12-05 |
イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ |
癌の治療のための抗ｖｅｇｆｒ−２抗体と抗ｐｄ−ｌ１抗体との組み合わせ
|
|
CN109963562A
(zh)
|
2016-11-16 |
2019-07-02 |
伊莱利利公司 |
用于具有外显子14跳读突变或外显子14跳读表型的癌症的组合疗法
|
|
US20200062836A1
(en)
|
2016-11-16 |
2020-02-27 |
Eli Lilly And Company |
THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
|
|
CA3043652A1
(en)
|
2016-11-18 |
2018-05-24 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
|
JP7256127B2
(ja)
|
2017-03-01 |
2023-04-11 |
ジェネンテック， インコーポレイテッド |
がんのための診断及び治療方法
|
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック， インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
|
CR20190481A
(es)
|
2017-03-22 |
2020-01-06 |
Genentech Inc |
Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
|
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
CN111295245B
(zh)
|
2017-08-29 |
2021-03-16 |
伯乐实验室有限公司 |
用于分离和分析细胞的系统和方法
|
|
WO2019057946A1
(en)
|
2017-09-25 |
2019-03-28 |
F. Hoffmann-La Roche Ag |
MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
|
|
CN107703290A
(zh)
*
|
2017-09-30 |
2018-02-16 |
安徽伊普诺康生物技术股份有限公司 |
一种血管内皮因子检测试剂盒的制备方法
|
|
CN107727847A
(zh)
*
|
2017-09-30 |
2018-02-23 |
安徽伊普诺康生物技术股份有限公司 |
一种血管内皮因子检测试剂盒及其使用方法
|
|
US20200355694A1
(en)
|
2017-11-20 |
2020-11-12 |
Konica Minolta, Inc. |
Drug Evaluation Method
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
CA3090878A1
(en)
|
2018-02-11 |
2019-08-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
|
|
JP2021514656A
(ja)
|
2018-03-02 |
2021-06-17 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
|
|
US20210009695A1
(en)
*
|
2018-03-19 |
2021-01-14 |
Pharmabcine Inc. |
Anti-vegfr-2 antibody
|
|
US11505610B2
(en)
|
2018-04-06 |
2022-11-22 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
JP7520366B2
(ja)
|
2018-04-16 |
2024-07-23 |
オンクオリティー ファーマシューティカルズ チャイナ リミテッド |
腫瘍療法の副作用の予防または治療方法
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2019293047A1
(en)
|
2018-06-29 |
2021-01-28 |
Gensun Biopharma Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
PH12021551422A1
(en)
|
2018-12-21 |
2022-05-02 |
23Andme Inc |
Anti-il-36 antibodies and methods of use thereof
|
|
US10633693B1
(en)
|
2019-04-16 |
2020-04-28 |
Celsee Diagnostics, Inc. |
System and method for leakage control in a particle capture system
|
|
BR112021020532A2
(pt)
|
2019-04-19 |
2022-03-15 |
Janssen Biotech Inc |
Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
|
|
JP2022530674A
(ja)
|
2019-05-03 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１抗体を用いたがんの処置方法
|
|
US11273439B2
(en)
|
2019-05-07 |
2022-03-15 |
Bio-Rad Laboratories, Inc. |
System and method for target material retrieval from microwells
|
|
EP3966307B1
(en)
|
2019-05-07 |
2024-11-20 |
Bio-Rad Laboratories, Inc. |
System and method for automated single cell processing
|
|
US11332546B2
(en)
|
2019-05-21 |
2022-05-17 |
The Regents Of The University Of California |
Protease inhibitory antibodies and methods of use thereof
|
|
WO2020237092A2
(en)
*
|
2019-05-21 |
2020-11-26 |
The Regents Of The University Of California |
Mmp-9 antibodies and methods of use thereof
|
|
KR20220024734A
(ko)
*
|
2019-06-26 |
2022-03-03 |
바이오 래드 래버러토리스 인코오포레이티드 |
마이크로웰에서 표적 물질을 회수하기 위한 시스템 및 방법
|
|
WO2020260595A1
(en)
|
2019-06-26 |
2020-12-30 |
Oncurious Nv |
Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
|
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
KR20220071177A
(ko)
*
|
2019-07-19 |
2022-05-31 |
사이노셀테크 엘티디. |
인간화 항-vegf 단클론 항체
|
|
WO2021013065A1
(zh)
*
|
2019-07-19 |
2021-01-28 |
神州细胞工程有限公司 |
人源化抗VEGF Fab抗体片段及其用途
|
|
KR20220024782A
(ko)
|
2019-07-22 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
자궁내막증의 비침습적 진단을 위한 혈액 바이오마커로서의 s100a8
|
|
EP4004552A1
(en)
|
2019-07-22 |
2022-06-01 |
F. Hoffmann-La Roche AG |
S100a12 as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
WO2021013781A1
(en)
|
2019-07-22 |
2021-01-28 |
F. Hoffmann-La Roche Ag |
Substance p as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
CN114144675A
(zh)
|
2019-07-22 |
2022-03-04 |
豪夫迈·罗氏有限公司 |
S100a9作为血液生物标志物用于子宫内膜异位症的非侵入性诊断
|
|
EP4004555A1
(en)
|
2019-07-22 |
2022-06-01 |
F. Hoffmann-La Roche AG |
S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
AU2020358854A1
(en)
|
2019-10-03 |
2022-05-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021094409A1
(en)
|
2019-11-15 |
2021-05-20 |
F. Hoffmann-La Roche Ag |
Derivatization of beta-lactam antibiotics for massspec measurements in patient samples
|
|
AU2020385991A1
(en)
*
|
2019-11-21 |
2022-06-23 |
Unity Biotechnology |
Antibodies directed to Tie-2 and methods of use
|
|
AU2021236306A1
(en)
|
2020-03-13 |
2022-09-15 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
JP2023519346A
(ja)
|
2020-03-27 |
2023-05-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
CN115843334A
(zh)
|
2020-04-23 |
2023-03-24 |
豪夫迈·罗氏有限公司 |
用于抗体免疫测定的冠状核衣壳抗原
|
|
IL298668A
(en)
|
2020-05-29 |
2023-01-01 |
23Andme Inc |
Antibodies against cd200r1 and methods of using them
|
|
US20230235040A1
(en)
|
2020-06-22 |
2023-07-27 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
EP3943946A1
(en)
|
2020-07-20 |
2022-01-26 |
F. Hoffmann-La Roche AG |
Gdf-15 for predicting the disease severity of a patient with covid-19
|
|
IL301269A
(en)
|
2020-09-14 |
2023-05-01 |
Ichnos Sciences S A |
Antibodies that bind to IL1RAP and their uses
|
|
US20230406909A1
(en)
|
2020-11-02 |
2023-12-21 |
Roche Diagnostics Operations, Inc. |
Sars-cov-2 nucleocapsid antibodies
|
|
WO2022103905A1
(en)
|
2020-11-13 |
2022-05-19 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
|
|
US20240018248A1
(en)
|
2020-12-02 |
2024-01-18 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
KR20230116899A
(ko)
|
2020-12-08 |
2023-08-04 |
제넨테크, 인크. |
고형 종양 치료를 위한 krasg12c 억제제 및 egfr-억제제를포함하는 방법 및 조성물
|
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
|
US20240052045A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
EP4267618A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
CA3210246A1
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
AR124914A1
(es)
*
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN112961243B
(zh)
*
|
2021-03-24 |
2022-04-29 |
山东兴瑞生物科技有限公司 |
一种vegf抗体、重组aav病毒及其应用
|
|
WO2022207628A1
(en)
|
2021-03-30 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Scf as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
JP2024511867A
(ja)
|
2021-04-01 |
2024-03-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのｐｓｐ９４
|
|
WO2022231930A1
(en)
|
2021-04-26 |
2022-11-03 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック， インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
|
EP4341700A1
(en)
|
2021-05-17 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Sfrp4 as blood biomarker for the non-invasive diagnosis of adenomyosis
|
|
WO2022256820A1
(en)
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
|
IL309071A
(en)
|
2021-07-02 |
2024-02-01 |
Genentech Inc |
Methods and compositions for the treatment of cancer
|
|
US12281161B2
(en)
|
2021-07-28 |
2025-04-22 |
Trustees Of Boston University |
Polypeptides and uses thereof
|
|
WO2023010095A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
|
US20250042976A1
(en)
|
2021-10-26 |
2025-02-06 |
Roche Diagnostics Operations, Inc. |
Monoclonal antibodies specific for sars-cov-2 rbd
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023107539A1
(en)
|
2021-12-10 |
2023-06-15 |
Bio-Rad Laboratories, Inc. |
Compositions, methods, and systems for sample processing with morphology-adjustable functionalized particles
|
|
WO2023144973A1
(ja)
|
2022-01-27 |
2023-08-03 |
中外製薬株式会社 |
抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
|
|
WO2023142996A1
(zh)
|
2022-01-28 |
2023-08-03 |
上海岸阔医药科技有限公司 |
预防或治疗与抗肿瘤剂相关的疾病或病症的方法
|
|
JP2025505812A
(ja)
|
2022-02-21 |
2025-02-28 |
オンクオリティ ファーマシューティカルズ チャイナ リミテッド |
化合物及びその用途
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
US20250235534A1
(en)
|
2022-04-13 |
2025-07-24 |
Vib Vzw |
An LTBR Agonist In Combination Therapy Against Cancer
|
|
CN119137139A
(zh)
|
2022-05-03 |
2024-12-13 |
豪夫迈·罗氏有限公司 |
用于免疫诊断测定的hiv gp41变体
|
|
EP4544305A1
(en)
|
2022-06-23 |
2025-04-30 |
F. Hoffmann-La Roche AG |
Method for diagnosing endometriosis and for classifying the stage of endometriosis
|
|
CN119604768A
(zh)
|
2022-07-22 |
2025-03-11 |
豪夫迈·罗氏有限公司 |
白三烯a4水解酶(lta4h)作为（血液）生物标志物用于诊断多囊卵巢综合征
|
|
JP2025523884A
(ja)
|
2022-07-22 |
2025-07-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
多嚢胞性卵巣症候群の診断のための（血液）バイオマーカーとしての線維芽細胞増殖因子結合タンパク質１（ｆｇｆｂｐ１）
|
|
JP2025524027A
(ja)
|
2022-07-22 |
2025-07-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
多嚢胞性卵巣症候群の診断のための（血液）バイオマーカーとしてのメテオリン様タンパク質（ｍｅｔｒｎｌ）
|
|
CN115850470B
(zh)
*
|
2022-12-12 |
2023-07-07 |
三门峡市眼科医院 |
Vegf抗体及其应用
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025026908A1
(en)
|
2023-07-28 |
2025-02-06 |
Roche Diagnostics Gmbh |
Serum epha1 as biomarker for endometriosis
|
|
WO2025049972A1
(en)
|
2023-09-01 |
2025-03-06 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
CN120131991A
(zh)
*
|
2023-12-13 |
2025-06-13 |
成都百利多特生物药业有限责任公司 |
抗人Claudin18.2抗体-喜树碱类药物偶联物及其医药用途
|